Literature DB >> 20167212

Tabun-inhibited rat tissue and blood cholinesterases and their reactivation with the combination of trimedoxime and HI-6 in vivo.

Jiri Bajgar1, Jana Zdarova Karasova, Jiri Kassa, Jiri Cabal, Josef Fusek, Vaclav Blaha, Sandra Tesarova.   

Abstract

Up to now, intensive attempts to synthesize a universal reactivator able to reactivate cholinesterases inhibited by all types of nerve agents/organophosphates were not successful. Therefore, another approach using a combination of two reactivators differently reactivating enzyme was used: in rats poisoned with tabun and treated with combination of atropine (fixed dose) and different doses of trimedoxime and HI-6, changes of acetylcholinesterase activities (blood, diaphragm and different parts of the brain) were studied. An increase of AChE activity was observed following trimedoxime treatment depending on its dose; HI-6 had very low effect. Combination of both oximes showed potentiation of their reactivation efficacy; this potentiation was expressed for peripheral AChE (blood, diaphragm) and some parts of the brain (pontomedullar area, frontal cortex); AChE in the basal ganglia was relatively resistant. These observations suggest that the action of combination of oximes in vivo is different from that observed in vitro. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167212     DOI: 10.1016/j.cbi.2010.02.009

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  2 in total

1.  Time-dependent changes of oxime K027 concentrations in different parts of rat central nervous system.

Authors:  Jana Zdarova Karasova; Filip Zemek; Kamil Musilek; Kamil Kuca
Journal:  Neurotox Res       Date:  2012-05-15       Impact factor: 3.911

2.  Acetylcholinesterase inhibitors: pharmacology and toxicology.

Authors:  Mirjana B Colović; Danijela Z Krstić; Tamara D Lazarević-Pašti; Aleksandra M Bondžić; Vesna M Vasić
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.